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Abstract
Background: While localized prostate cancer (PCa) can be effectively cured, metastatic disease inevitably
progresses to a lethal state called castration-resistant prostate cancer (CRPC). Emerging evidence suggests that
aberrant epigenetic repression by the polycomb group (PcG) complexes fuels PCa progression, providing novel
therapeutic opportunities.
Results: In the search for potential epigenetic drivers of CRPC, we analyzed the molecular profile of PcG
members in patient-derived xenografts and clinical samples. Overall, our results identify the PcG protein and
methyl-lysine reader CBX2 as a potential therapeutic target in advanced PCa. We report that CBX2 was recurrently
up-regulated in metastatic CRPC and that elevated CBX2 expression was correlated with poor clinical outcome in
PCa cohorts. Furthermore, CBX2 depletion abrogated cell viability and induced caspase 3-mediated apoptosis in
metastatic PCa cell lines. Mechanistically explaining this phenotype, microarray analysis in CBX2-depleted cells
revealed that CBX2 controls the expression of many key regulators of cell proliferation and metastasis.
Conclusions: Taken together, this study provides the first evidence that CBX2 inhibition induces cancer cell
death, positioning CBX2 as an attractive drug target in lethal CRPC.
Keywords: Castration-resistant prostate cancer, CBX2, Epigenetics, Metastatic prostate cancer, Polycomb
Background
At present, prostate cancer (PCa) represents the most
commonly diagnosed non-cutaneous malignancy in men
[1]. While localized disease can be effectively treated
with surgery or radiotherapy, metastatic PCa remains
invariably fatal [2]. For the past 30 years, androgen-
deprivation therapy (ADT) has been the standard care
for disseminated PCa. However, all tumors eventually
acquire resistance to ADT and relapse in a highly aggres-
sive state called castration-resistant prostate cancer
(CRPC) [3]. Despite the introduction of novel thera-
peutic agents for late-stage patients, CRPC remains an
incurable malignancy and thus a better understanding of
its molecular drivers is required to facilitate the develop-
ment of novel treatment strategies [4, 5]. Over the past
decade, mounting evidence has demonstrated that
epigenetic alterations significantly contribute to PCa
progression, suggesting that the PCa epigenome may
harbor clinically relevant therapeutic targets [6].
Epigenetics refers to changes in transcriptional
programs that cannot be attributed to modifications in
DNA sequence [7]. Epigenetic changes result in cellular
and physiological phenotypic trait variations in response
to external or environmental factors that switch genes
on and off. Epigenetic regulation influences gene
expression by controlling access of the transcriptional
machinery to distinct genomic regions [8]. During
embryonic development, epigenetic mechanisms define
gene expression programs which themselves specify
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differentiation into distinct tissues [9]. In human can-
cers, these epigenetic states become disrupted, thereby
promoting disease initiation and progression by altering
the expression of key oncogenes and tumor suppressors
[10, 11]. Given the clinical approval of a growing num-
ber of epigenetic drugs, there is considerable value in
identifying novel chromatin-regulating complexes driv-
ing disease progression [12].
Emerging evidence suggests that epigenetic dysregula-
tion mediated by the polycomb group (PcG) family of
transcriptional repressors plays a critical role during PCa
progression [13]. Conserved throughout evolution, PcG
proteins assemble in two main polycomb repressive com-
plexes, PRC1 and PRC2 [14]. In the classical model, PRC2
trimethylates histone H3 at lysine 27 (H3K27me3) via the
catalytic activity of EZH2, thereby triggering transcrip-
tional silencing [15]. H3K27me3 can then be recognized
by the N-terminal chromodomain of five CBX proteins
(CBX2, 4, 6, 7, 8), which are members of PRC1 [16]. Upon
binding H3K27me3, CBX proteins can recruit PRC1 to
chromatin through protein-protein interactions. PRC1
recruitment further promotes transcriptional repression
through various mechanisms such as histone H2A ubiqui-
tination and chromatin compaction, some of which are
known to play a role in PCa progression [17, 18]. In ad-
vanced PCa, EZH2 is overexpressed and pharmacological
inhibition of PRC2 impairs tumorigenicity and metastatic
ability [13, 19]. Moreover, the PRC1 member BMI1
promotes resistance to docetaxel, a drug used in CRPC
treatment via modulation of key transcriptomic programs
[20]. While the tumor-promoting roles of EZH2 and
BMI1 have been well established, the functional implica-
tion of individual PcG members during PCa progression
and their contribution to CRPC have yet to be evaluated.
Since CBX proteins bridge the activity of PRC2 and
PRC1, they represent critical regulators of PcG-mediated
silencing [21]. We have previously demonstrated that
CBX2 expression was significantly up-regulated in aggres-
sive tumors of many cancer types, including PCa [22].
These novel findings complement studies from CBX2-de-
ficient animals demonstrating critical functions for CBX2
in cellular proliferation and differentiation [23, 24]. It has
been shown that animal models lacking CBX2 display
multi-organ hypocellularity as a result of a proliferative
block. In mice, germline deletion of the CBX2 homolog
M33 results in homeotic transformations and sexual
defects [25, 26]. Strikingly, it was shown across multiple
species that individuals with XY karyotype lacking CBX2
were unable to undergo development of the male urogeni-
tal system, implying a role in prostatic cell proliferation
and differentiation [26, 27]. Taken together, these findings
indicate that CBX2 may be functionally involved in
aberrant PcG-mediated silencing thought to promote PCa
progression and drug resistance.
With the aim of identifying new epigenetic targets, we
analyzed the molecular profiles of PcG family members
in patient-derived xenograft (PDX) models and clinical
samples of advanced PCa. Using validated in vitro and
in vivo models [28, 29], we demonstrate that the PRC1
member and epigenetic reader CBX2 is recurrently over-
expressed in metastatic and androgen-independent PCa
cells and that elevated CBX2 expression predicts poor
clinical outcome. Furthermore, we show that CBX2
depletion induces PCa cell death and proliferation arrest
by regulating the expression of a key subset of genes,
suggesting that CBX2 may emerge as a novel therapeutic
target for advanced PCa.
Results
CBX2 is overexpressed in aggressive PCa
As the first step to identify putative therapeutic targets
for advanced PCa, we analyzed the expression of PcG
genes in the LTL313H/LTL313B PDX model of meta-
static and non-metastatic PCa [29]. LTL313H and
LTL313B represent two xenografted tissues that were
derived from two independent needle biopsies of the
same primary PCa tumor (Fig. 1a). This unique PDX
pair therefore recapitulates and exploits the intra-
tumoral heterogeneity observed in clinical PCa as
LTL313H consistently gives rises to metastases when
implanted in the mouse subrenal capsule while LTL313B
always stays local to the grafting site. Interestingly, gen-
omic characterization has previously determined that
the genetic profile of LTL313B and LTL313H displays
more than 95 % homology [29], implying that epigenetic
alterations are likely to be involved in the process of
metastatic dissemination. Thus, this model provides a
unique experimental system to identify differential
expression of PcG genes between distinct foci of differ-
ent metastatic ability within a single primary prostate
tumor [29].
Microarray analysis was performed on RNA extracted
from LTL313B and LTL313H to identify differential
expression of PcG genes. This analysis demonstrated
that the chromodomain-containing protein, and known
regulator of male urogenital system development, CBX2,
was the most highly up-regulated PcG transcript in
LTL313H compared to LTL313B (Fig. 1b). To validate
these results, we assessed CBX2 expression in both
tumor lines using quantitative reverse transcription poly-
merase chain reaction (qRT-PCR), which confirmed that
CBX2 expression was 3.2-fold higher in LTL313H com-
pared to LTL313B (Fig. 1c, p < 0.0001, Student’s t test).
Consistent with messenger RNA (mRNA) levels, CBX2
protein expression was undetectable in LTL313B while
LTL313H showed strong CBX2 immunostaining, in line
with a possible role in PCa dissemination (Fig. 1d, ×20).
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To ensure that overexpression of CBX2 in metastatic
PCa tissues was not solely a property of the LTL313B/
LTL313H xenograft model, we assessed the expression
of CBX2 in primary and metastatic tumors from PCa pa-
tients using the Oncomine database [30]. As observed in
the xenografts, CBX2 expression was significantly higher
in metastatic compared to non-metastatic tumors in
three independent clinical cohorts (Fig. 1e, p ≤ 0.05,
Student’s t test). Importantly, we could not find a single
study in which CBX2 was significantly down-regulated
in metastatic tissues. Thus, the CBX2 up-regulation
observed in the LTL313B/LTL313H PDX model was also
recapitulated in patient tumors.
After observing elevated CBX2 levels in advanced PCa
models, we sought to determine whether CBX2 overex-
pression correlated with specific indicators of poor
outcome. We conducted multivariate analysis of vari-
ance (MANOVA) to associate the expression of CBX2
with specific clinicopathologic features in clinical PCa
patients using previously published clinical data [31].
This analysis revealed that elevated CBX2 levels were
significantly correlated with lower patient age, higher
Gleason grade, and a positive nodal status (Table 1, p <
0.05, MANOVA). All these variables are themselves
indicators of poor prognosis in patients; these data
support the idea that elevated CBX2 expression is
observed in aggressive prostate tumors.
Hormonal regulation of CBX2 expression
Since metastatic PCa patients inevitably develop lethal
CRPC [3], we investigated the involvement of CBX2 in
the progression to androgen-independent disease. To
address this question, we took advantage of another
patient-derived xenograft model in which the primary
tumor line, LTL313B, was subjected to ADT (Fig. 2a)
[29]. As observed in the clinic, ADT elicited a significant
reduction in LTL313B tumor volume shortly after
castration. However, the tumor developed resistance and
Fig. 1 CBX2 is overexpressed in metastatic PCa. a Establishment of the LTL313B/LTL313H PDX model of metastatic PCa; b Expression of core PcG
family members in the LTL313H/LTL313B xenograft model; Results are based on a single microarray experiment; c Confirmation of CBX2 mRNA
up-regulation in the LTL313H tumor line by qRT-PCR; d Confirmation of CBX2 protein up-regulation in the LTL313H tumor line by IHC (20x). Images
are representative of multiple fields taken from 2 independent experiments; e Elevated CBX2 mRNA levels in metastatic PCa compared to non-
metastatic samples in three independent patients
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eventually re-emerged as the CRPC tumor line LTL313BR
[29]. LTL313BR retains important properties of CRPC
such as expression of PSA and androgen-independent
growth, as well as resistance to AR antagonists and
docetaxel [29]. Additional information regarding this
model is available at the Living Tumor Laboratory website
(www.livingtumorlab.com).
As the first step to link CBX2 and CRPC pathogenesis,
we quantified the expression of CBX2 in the LTL313B/
LTL313BR xenograft model and observed that CBX2
expression was elevated in LTL313BR relative to
LTL313B using qRT-PCR (Fig. 2b, p < 0.001, Student’s t
test). Furthermore, immunohistochemical (IHC) staining
revealed that CBX2 protein levels were undetectable in
LTL313B while LTL313BR exhibited strong CBX2 nu-
clear staining (Fig. 2c). To confirm the results obtained
in the 313B/BR model, we assessed the expression of
CBX2 in a panel of PCa PDX models that were either
androgen-dependent (n = 10) or androgen-independent
(n = 5) available at the Living Tumor Laboratory. In line
with the 313B/BR model, CBX2 expression was signifi-
cantly higher in the androgen-independent PDX models
(Fig. 2d, p < 0.05, Student’s t test), consistent with a role
in castration-resistant disease.
To complement the observations made in PDX
models, we conducted in vitro studies investigating the
androgenic regulation of CBX2. First, we quantified the
expression of CBX2 in LNCaP and C4-2 cell lines com-
pared with benign prostate hyperplasia cells (BPH1).
The isogenic LNCaP/C4-2 model was chosen for these
studies since it represents a validated and clinically rele-
vant model of PCa progression. LNCaP was originally
derived from a lymph node metastasis. It was subse-
quently implanted into a castrated mouse, giving rise to
a castrate-resistant cell line C4-2 following ADT [32].
Both LNCaP and C4-2 express AR, but only LNCaP
exhibits androgen-responsive growth [32]. Moreover,
Table 1 Multivariate analysis of variance correlating CBX2 and
clinicopathological features in primary PCa from MSKCC cohort
Factor F value p value Significance
Age 4.8235 0.030674 *
Extension 1.9261 0.131084
Gleason 5.5086 0.021142 *
Nodal 15.4775 0.000165 ***
Race 0.7067 0.55053
Sem Vesicle 0.0262 0.871665
SurgMargins 0.0839 0.772712
T stage 0.5005 0.607944
FDR false discovery rate
***p ≤ 0.001; *p ≤ 0.05
Fig. 2 Hormonal regulation of CBX2. a Establishment of the LTL313B/LTL313BR patient-derived xenograft model of CRPC; b Assessment of CBX2
mRNA levels in the LTL313B/LTL313BR xenograft model by qRT-PCR; c IHC staining of CBX2 in the LTL313B and LTL313BR xenografts ×20. Images
are representative of multiple fields taken from two independent experiments; d Levels of CBX2 mRNA in androgen-dependent (AD, n = 10) and
androgen-independent (AI, n = 5) PDXs from the LTL; e Relative CBX2 expression in PCa cell lines compared to benign control (BPH1) assessed by
qRT-PCR; f CBX2 mRNA levels in LNCaP cells cultured in charcoaled-stripped media in the presence or absence of DHT supplementation (10 nM)
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C4-2 xenografts display higher tumor formation and
produce more metastatic foci in vivo, consistent with the
idea that androgen-independent cells are inherently
more aggressive [28]. Androgen-independent C4-2 cells
displayed CBX2 mRNA levels 41 times higher than
BPH1 while androgen-dependent LNCaP exhibited a
nine-fold up-regulation in CBX2 expression (Fig. 2e, p <
0.0001 for both, Student’s t test). Next, CBX2 expression
was assessed in vitro using androgen-responsive LNCaP
cells subjected to removal and addition of dihydrotes-
tosterone (DHT), a potent AR agonist. In LNCaP cells,
CBX2 mRNA levels significantly increased after 48 h of
culture in androgen-depleted media, as assessed by
qRT-PCR (Fig. 2f, p < 0.001, Student’s t test). Accord-
ingly, this dramatic effect was not observed in cells
supplemented with DHT, suggesting that a decrease in
ligand-induced AR transactivation reversibly stimulates
CBX2 expression.
Given the elevated expression of CBX2 in PCa, we set
out to determine whether any genetic aberrations could
be underlying CBX2 up-regulation. We queried four
independent patient cohorts for which both copy num-
ber changes and mutations were available. A striking
observation was that not a single point mutation could
be found within the CBX2 locus in any of the four data-
sets, which were comprised of a total of 329 patients
(Table 2). Additionally, only 3 out of 329 patients (0.9 %)
were found to have a CBX2 copy number loss (CNL).
Similarly, only 5 out of 329 patients (1.5 %) exhibited
CBX2 copy number gain, which is not sufficient to
account for the CBX2 up-regulation observed in clinical
PCa (Table 2). Taken together, these findings highlight
the rarity of genomic disruption of CBX2 and suggest
that CBX2 itself is likely to be under epigenetic and/or
hormonal regulation.
CBX2 depletion induces cell death in advanced PCa cell
lines
To evaluate the functional requirements of CBX2 in
advanced PCa cells, we analyzed the phenotypic effects
of small interfering RNA (siRNA)-mediated CBX2 silen-
cing in two metastatic PCa cell lines, LNCaP and C4-2.
In LNCaP cells, both CBX2 mRNA and protein levels
were reduced by more than 90 % following siRNA treat-
ment (Fig. 3a, c, p < 0.0001, Student’s t test). For C4-2
cells, CBX2-specific siRNA induced a 60 % reduction in
CBX2 mRNA levels while CBX2 protein levels were vari-
ably reduced (Fig. 3b, d, p < 0.0001, Student’s t test). Ap-
proximately 55 h following transfection, both LNCaP
and C4-2 cells treated with CBX2-specific siRNA started
exhibiting notable morphological changes not observed
in cells treated with non-targeting siRNA. In both the
LNCaP and C4-2 lines, cells started to round up and
lose their epithelial appearance (Fig. 4). As these mor-
phological changes occurred, the cells stopped proliferat-
ing and started detaching from the plate after about
3 days post-transfection, leaving very few viable cells
4 days after siRNA treatment.
To quantify the extent of cell viability loss resulting
from CBX2 depletion, we conducted 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
analysis on LNCaP and C4-2 cells treated with mock,
non-targeting control, or CBX2-specific siRNA. MTT
assay confirmed a significant reduction in cell viability
following CBX2 knockdown in both cell lines (Fig. 3e, f,
p < 0.0001, Student’s t test). More specifically, the prolif-
eration arrest induced by CBX2 depletion started to
appear 3 days after siRNA treatment and culminated in
a dramatic decrease in cell viability after 5 days in both
cell lines, thus confirming the microscopic observations.
To explore the possibility that CBX2 might regulate
apoptotic cell death, caspase 3/7 activity was analyzed in
LNCaP and C4-2 cells treated with either control or
CBX2-specific siRNA for 72 h. Notably, CBX2 depletion
induced a 3.7- and 2.3-fold increase in caspase 3/7
activity in LNCaP and C4-2, respectively (Fig. 3g, h,
p < 0.001, Student’s t test), suggesting that CBX2 is
required for PCa cell survival. Taken together, these
findings indicate that CBX2 is functionally involved in
the regulation of PCa cell morphology, proliferation,
and apoptosis.
Gene expression profiling of CBX2-depleted cells
Given the striking phenotypes observed upon CBX2
depletion, we further investigated the molecular mecha-
nisms and transcriptomic changes controlled by CBX2
in CRPC. To identify CBX2-regulated genes (CRGs), we
conducted microarray profiling in the CRPC cell line
model C4-2 treated with control or CBX2-specific
siRNA (Fig. 5a). RNA was extracted 55 h after siRNA
Table 2 Genomic alterations affecting the CBX2 locus in PCa
PCa dataset and journal No. of patients % Mut % CNG % CNL
MSKCC—Cancer Cell 2010 103 0 2 1
Michigan—Nature 2012 61 0 5 0
Broad/Cornell—Nat. Gen. 2012 109 0 0 0
Broad/Cornell—Cell 2013 56 0 0 4
Total 329 0 2 1
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transfection, a time point where CBX2 expression is
reduced in siCBX2-treated cells but just prior to when
these cells start to display abnormal proliferation and
morphology (Fig. 3). Three replicate samples were
obtained for each condition to ensure reproducibility.
To validate optimal RNA quality, we assessed the purity
and integrity of the RNA via Nanodrop and Bioanalyzer,
respectively. Nanodrop analysis revealed that all repli-
cates had A280/A230 and A260/A230 ratios higher than
2.0, indicating high RNA purity. In addition, Bioanalyzer
studies demonstrated that all six samples had an RIN
value higher than 9.4 out of 10 (average = 9.65), indicat-
ing high quality and minimal degradation across all
replicates.
After validating RNA quality and knockdown effi-
ciency, we conducted microarray analysis using the
Agilent platform. First, we conducted qRT-PCR and
validated an 80 % inhibition of CBX2 expression in cells
treated with CBX2-specific siRNA (Fig. 5b, p < 0.0001,
Student’s t test). Using an unpaired t test with
Benjamini-Hochberg correction, we identified 544 tran-
scripts that were differentially expressed upon CBX2 si-
lencing and were termed CBX2-regulated genes (CRGs,
Fig. 5a). Among them, 232 were up-regulated and 312
were down-regulated (Fig. 5a). Unsupervised hierarchical
clustering revealed that the up-regulated and down-
regulated genes have distinct expression patterns which
are extremely consistent across all replicates (Fig. 5c).
To ensure that the expression changes observed in the
microarray profiling were reproducible, we first selected
individual CRGs previously associated with cancer
whose expression could be validated by qRT-PCR. Inter-
estingly, a number of important regulators of cell prolif-
eration and metastasis were significantly modulated after
Fig. 3 CBX2 depletion induces proliferation arrest and apoptosis in advanced PCa cell lines. a, b Confirmation of CBX2 mRNA knockdown in
LNCaP and C4-2 cells by qPCR; c, d Confirmation of CBX2 protein knockdown in LNCaP and C4-2 cells; e, f MTT analysis of cell viability following
CBX2 silencing in LNCaP and C4-2 cells; g, h Assessment of caspase 3–7 activity in LNCaP and C4-2 cells following CBX2 depletion
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CBX2 depletion. Notably, ITGB8, DICER1, INPP5A,
PIK3R1, and TIMP2 are key tumor suppressors that
were among up-regulated CRGs following CBX2 knock-
down. Significant up-regulation of these genes in
CBX2-depleted cells was also validated using qRT-PCR
(Fig. 5d, p ≤ 0.05 for all, Student’s t test). Conversely,
the tumor-associated proteins MKI67, FOXM1, CENPF,
TERT, and CEP55 were down-regulated following
CBX2 silencing, which was also successfully confirmed
by qRT-PCR (Fig. 5e, p ≤ 0.05 for all, Student’s t test).
Thus, qRT-PCR replicated the transcriptomic changes
detected through microarray analysis, providing
another quality control to ensure the validity of the
microarray results.
Biological properties of CBX2-regulated genes
As the first step to analyzing the properties of CRGs,
we assessed whether CRGs were associated with human
diseases using Ingenuity Pathway Analysis (IPA) soft-
ware. Interestingly, we found that cancer was the
disease most significantly linked to CRGs (Table 3), in
line with our previous finding that CBX2 is involved in
a wide range of cancer types [22]. Moreover, other
diseases most associated with CRGs included “Develop-
mental Disorder” and “Reproductive System Disease,”
both of which have previously been linked to CBX2
mutations in the medical literature [27]. Next, we
assessed the biological properties associated with CRGs.
Using the Oncomine software set at the analysis of
“biological processes and functions,” a significant link
between CBX2 and cell cycle progression was observed.
Out of the top 13 processes most significantly
correlated with CRGs, 11 were directly involved in the
regulation of cell cycle progression (Table 4, inclusion
criteria: odds ratio (OR) > 2, p < 0.05). These included
“DNA replication and chromosome cycle,” “Mitotic
chromosome condensation,” and “Mitotic sister chro-
matid segregation” (Table 4, all p < 0.001, all OR > 23).
Thus, pathway analysis revealed that CRGs were
enriched in genes involved in the control of cellular
proliferation.
Since biological processes associated with mitosis
were overrepresented in CRGs, we analyzed the
expression of key genes involved in cell division. A
striking feature was that several key components of
the mitotic machinery were also significantly down-
regulated upon CBX2 silencing. These genes encoded
numerous members of the following group of mitotic
proteins: centromere proteins (CENPA, E, H, I, K, L,
N, O, P, Q, W), kinesin family (KIF22, 23), spindle
and kinetochore associated complex subunit (SKA1, 2,
3), and structural maintenance of chromosomes
(SMC2, 4) (Table 5, all p < 0.05, unpaired t test). A
number of additional mitotic signaling proteins such
as AURKA, AURKB, CCNB1, MKI67, CDK1, and
CDC25A were also significantly down-regulated
(Table 5, all p < 0.05, unpaired t test). Interestingly,
the expression of the PLK family of kinases (PLK1, 3,
4) was also repressed upon CBX2 silencing (Table 5,
all p < 0.05, unpaired t test). The inability to undergo
mitosis caused by widespread down-regulation of
proteins involved in mitotic integrity could therefore
partly explain the strong proliferative defect induced
by CBX2 knockdown.
Fig. 4 Morphology of LNCaP and C4-2 cells following CBX2 depletion (96 h post-siRNA treatment). Images are representative of multiple fields
taken from three independent experiments (×20 for large image and ×40 for small image)
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Clinical analysis of CBX2-regulated genes
To determine whether gene expression changes observed
upon CBX2 silencing had clinical relevance, we ana-
lyzed the expression of CRGs in a large clinical dataset
containing both primary and metastatic tumors [31].
First, we sorted patients based on their CBX2 mRNA
expression. In line with our previous findings, meta-
static PCa had significantly higher CBX2 expression
compared to primary PCa (Fig. 6a, p < 0.0001, Mann-
Whitney U test). Next, we performed Ward’s clustering
to observe the distribution of CRGs based on CBX2
expression. The resulting heatmap clearly demonstrated
that a large proportion of CRGs show apparent cluster-
ing, indicating that CRGs are correlated with CBX2
expression. To quantify the relationship between CBX2
and individual CRGs in patient tumors, we calculated
the Pearson correlation coefficient (ρ) between CBX2
expression and expression of each CRG across patients.
As expected, the expression of a number of CRGs was
strongly correlated with CBX2 expression (i.e., ρ higher
than 0.5 or ρ lower than −0.5). More specifically, 75
Fig. 5 Gene expression profiling of CBX2-regulated genes. a Experimental design of microarray analysis; b Validation of CBX2 silencing in samples
subjected to microarray analysis; c Unsupervised hierarchical clustering of genes differentially expressed following CBX2 knockdown; d Differential
expression of up-regulated CRGs confirmed by qRT-PCR in CBX2-depleted C4-2 cells; e Differential expression of down-regulated CRGs confirmed
by qRT-PCR in CBX2-depleted C4-2 cells
Table 3 Top diseases associated with CBX2-regulated genes
(IPA analysis)
Rank Category p value
1 Cancer 5.86E-10–1.71E-02
2 Development disorder 1.60E-08–1.70E-02
3 Hematological disease 1.60E-08–1.03E-02
4 Hereditary disorder 1.60E-08–1.70E-02
5 Gastrointestinal disease 3.55E-08–8.34E-03
6 Reproductive system disease 4.46E-08–1.70E-02
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genes (15.9 %) had a ρ lower than 0.5, and 105 (22.6 %)
had a ρ lower than −0.5. These findings confirm that
the CRGs found upon CBX2 silencing in vitro (see
Fig. 4) are also correlated with CBX2 expression in
patient tumors, suggesting that CBX2 is the causative
agent behind clinical gene expression programs.
Finally, we determined whether CBX2 expression
had an impact on clinical outcome. We first created a
density plot demonstrating the spectrum of CBX2
expression in PCa. Since there was a natural cutoff at
CBX2 expression around 2, we separated patients
based on this cutoff and performed logrank test
(Fig. 6c). Analysis of the resulting Kaplan-Meier curve
indicated that patients with higher CBX2 expression
displayed a significantly lower disease-free survival
compared to patients with lower CBX2 levels (Fig. 6d,
p = 0.0021, logrank test). Taken together, these find-
ings demonstrate that CBX2 expression correlates
with specific gene expression programs in patients
and is associated with poor clinical outcome.
Discussion
Despite numerous large-scale sequencing efforts, very
few genetic mutations are recurrently found in PCa, sug-
gesting that epigenetic alterations likely contribute to
PCa progression [33]. Recent studies have highlighted a
critical role for the PcG family of epigenetic repressors
in PCa cell survival and metastasis [17]. We therefore
analyzed the expression of all PcG members in paired
primary/metastatic PDXs and clinical datasets of PCa.
Our results demonstrate that CBX2 is the most highly
up-regulated PcG member across multiple models of
metastatic and castration-resistant PCa and that elevated
CBX2 levels correlate with poor clinical outcome. More-
over, we show for the first time that CBX2 depletion in-
duced PCa cell death in vitro, which was accompanied
by differential expression of key genes regulating PCa
progression. Taken together, these results position CBX2
as a putative therapeutic target in advanced PCa.
CBX2 up-regulation was first identified in our paired
non-metastatic (LTL313B) and metastatic (LTL313H)
PDXs implanted into the subrenal capsule of NOD-
SCID mice [29]. We have previously shown that this
type of PDX conserves the molecular profile of the
parental patient tumor. A particular feature of the
LTL313B/H model is that both tumor lines originate
from different foci of a single localized tumor, thus
Table 4 Biological processes associated with CBX2-regulated genes (Oncomine analysis)
Rank Concept name p value Q value Odds ratio
1 DNA replication and chromosome cycle 2.3E-06 1.2E-04 39.0
2 Mitotic chromosome condensation 8.2E-04 2.4E-02 23.2
3 Mitotic sister chromatid segregation 8.2E-04 2.4E-02 23.2
4 G1/S transition of mitotic cell cycle 1.0E-02 1.8E-01 7.7
5 Nucleotide-excision repair 1.0E-02 1.8E-01 7.7
6 Mitosis 1.5E-06 7.9E-05 6.5
7 DNA repair 4.7E-08 3.1E-06 6.3
8 DNA replication 2.7E-06 1.4E-04 6.1
9 Cytokinesis 7.2E-07 4.1E-05 5.8
10 Chromosome organization and biogenesis 1.0E-03 4.0E-02 4.6
11 Cell Cycle 2.3E-05 1.0E-03 3.9
12 Regulation of cell cycle 4.0E-03 8.0E-02 2.6
13 Intracellular signaling cascade 6.1E-04 1.9E-02 2.4
Table 5 Expression of CBX2-regulated genes involved in mitosis
following CBX2 silencing
Gene Fold change p value Gene Fold change p value
CENP family SMC family
CENPA −3.1 2.1E-03 SMC1 −2.0 3.3E-02
CENPE −3.0 1.6E-04 SMC2 −2.7 1.4E-04
CENPH −2.9 4.4E-03 SMC3 −1.3 3.4E-03
CENPI −3.0 1.7E-03 SMC4 −2.9 1.1E-03
CENPK −2.4 1.0E-03 SMC6 −1.5 3.0E-03
CENPL −1.8 5.6E-03 Mitotic signaling proteins
CENPN −1.9 1.1E-04 AURKA −2.6 3.7E-04
CENPO −2.4 4.2E-03 AURKB −3.4 1.3E-03
CENPP −1.6 2.4E-02 CCNB1 −2.4 5.0E-04
CENPQ −1.8 1.1E-03 KI67 −2.0 1.2E-04
CENPW −2.8 1.1E-03 CDK1 −2.3 2.2E-04
SKA family CDC25A 2.2 6.7E-04
SKA1 −3.0 1.4E-04 PLK1 −2.7 1.0E-02
SKA2 −2.1 4.9E-03 PLK3 −1.4 4.8E-05
SKA3 −2.8 3.5E-05 PLK4 −2.9 1.5E-03
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properly recapitulating the intra-tumoral heterogeneity
observed in clinical PCa [29]. In the LTL313B/H model,
we observed a high expression of CBX2 solely in the
metastatic tumor line LTL313H. Based on this model,
our results suggest that a small population of CBX2-
expressing PCa cells within the primary tumor is the
likely seed of metastatic dissemination. Consistent with
this notion, we have also shown that CBX2 expression is
elevated in metastatic tumors compared to those
remaining local to the prostate. This is in accordance
with our in vitro studies, which demonstrate that CBX2
depletion induced death in two metastatic PCa cell lines.
Further supporting this idea, CBX2 inhibition resulted in
up-regulation of PI3K antagonists such as PIK3R1 and
INPP5A. In turn, this would result in activation of the
pro-metastatic PI3K/AKT pathway, which is known to
be altered in the vast majority of CRPC patients [34].
Currently, a major clinical challenge lies in identifying
patients who will develop lethal, disseminated PCa and
those who will not progress to metastatic disease [35].
Given the strong association between CBX2 and aggres-
sive PCa, the expression of CBX2 could provide prog-
nostic information. We found that elevated CBX2 levels
independently predicted high grade, metastatic dissem-
ination, and disease-free survival in PCa patients. How-
ever, as observed in the LTL313B/H model, there exists
intra-tumoral heterogeneity within primary PCa such
that molecular analyses resulting from a single biopsy
site may not detect all CBX2-overexpressing foci. There-
fore, we propose that positive CBX2 IHC staining in at
least one core biopsy could be incorporated as an
unfavorable prognostic marker that could be interpreted
in the context of currently used methods such as TNM
staging and Gleason score.
Fig. 6 Clinical analysis of CBX2 and CBX2-regulated genes in the MSKCC prostate adenocarcinoma cohort. a Heatmap showing the expression of
the 544 genes differentially expressed after knocking-down CBX2. Here, only the 140 patients with gene expression data are shown. The columns
(patients) were sorted based on CBX2 expression (red: high expression, blue: low expression). Metastatic prostate cancer patients had significantly
higher CBX2; b CBX2 expression correlated with the expression of the differently expressed genes; c CBX2 expression distribution across the 140
patients. Here, we used a CBX2 expression threshold of 2 to call CBX2 up-regulation since there was a natural gap around expression value of 2;
d Patients with CBX2 expression up-regulation had significantly lower disease-free survival
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In line with the idea that CBX2 promotes tumor
progression, the biological processes and functions
associated with CRGs were intricately related with
proliferation. These properties are consistent with
phenotypic features of CBX2-deficient animals which
exhibit multi-organ hypocellularity as a result of a
proliferative block [25]. Further linking CBX2 and cell
cycle progression, the analysis of CRGs revealed that
a large number of proteins involved in mitotic spindle
assembly are significantly down-regulated upon CBX2
silencing. In the literature, there is evidence demon-
strating that CBX2 directly contributes to cell cycle
progression through its association with condensed
chromatin [36, 37]. Here, we expand on this mitotic
function and show that, in addition, CBX2 also ensures
integrity of cell division indirectly via the regulation of
CRGs involved in mitotic spindle assembly. Moreover,
CRGs included targetable kinases of the aurora kinase
(AURKA, B) and the polo-like kinase (PLK1, 3, 4) fam-
ilies, all of which have been shown to promote G2/M
transition. Taken together, these results suggest that
CBX2 represents a key regulator of mitosis in CRPC, in
line with its reported role in cellular proliferation.
A striking phenotype of CBX2-KO animals and
humans is that XY subjects undergo male-to-female
reversal, implying that CBX2 is required for the de-
velopment of the male urogenital system [27]. While
this feature suggests that CBX2 may cooperate with
AR activity, our data indicates that CBX2 is antagon-
istically regulated by ligand-dependent AR signaling.
Given the pro-survival properties conferred by CBX2
in vitro, we posit that CBX2 up-regulation may serve
as an adaptive mechanism to bypass the anti-tumor
response elicited by castration. Currently, an emerging
clinical problem is that CRPC patients are becoming
increasingly susceptible to transdifferentiation into
highly aggressive neuroendocrine prostate cancer
(NEPC) as a result of treatment with novel AR
suppressors [38]. We have recently demonstrated that
a number of PcG genes including CBX2 were overex-
pressed in NEPC [39]. Given the up-regulation of
CBX2 in both CRPC and NEPC, we posit that CBX2 is
required for tumor cell survival following castration but
that other molecular mechanisms define specialization
into neuroendocrine or epithelial lineages. As a conse-
quence, development of CBX2 antagonists may benefit
patients with late-stage disease by simultaneously blocking
the progression of CRPC and NEPC.
While CBX2 antagonism represents a promising
therapeutic strategy, there are no inhibitors of CBX2
currently available. From a drug development stand-
point, CBX2 possesses a chromodomain that binds
H3K27me3 with high affinity and could be pharmaco-
logically targeted. Adding value to this strategy,
studies have shown that PRC1 complexes found at
H3K27me3 sites were enriched in CBX2 compared to
other CBX family members. To date, antagonists have
been developed for a number of chromodomains,
including that of CBX7. Since the chromodomains of
CBX7 and CBX2 are largely conserved but display
some structural differences, it is possible to synthesize
small molecules with selectivity for CBX2. Thus, these
compounds could disrupt the interaction between
CBX2 and H3K27me3, providing a specific mechan-
ism to inhibit CBX2 activity and reverse abnormal
gene expression programs. In conclusion, this study
provides the first evidence that the H3K27me3 reader
CBX2 is functionally involved in any human cancer,
thereby adding to the growing landscape of cancer
epigenetics.
Conclusions
There are currently no curative options for castration-
resistant prostate cancer and thus there is a dire need
to identify new potential therapeutic targets. We identi-
fied the polycomb group (PcG) member and epigenetic
reader CBX2 as the most highly expressed PcG gene in
metastatic and castration-resistant prostate cancers.
Elevated expression correlated with aggressive disease
and poor clinical outcomes. Functional analysis
revealed that CBX2 is critical for prostate cancer cell
survival. Our work positions CBX2 as a novel potential
therapeutic target in CRPC.
Methods
Patient-derived xenograft models
As previously reported, the Living Tumor Lab (LTL,
www.livingtumorlab.com) has developed a collection of
high-fidelity PDXs implanted into the subrenal capsule
of NOD-SCID mice [29]. We used the LTL313B/
LTL313H model to investigate the role of CBX2 in
metastasis and the LTL313B/BR model to assess the
implications of CBX2 in drug-resistant CRPC [29].
Tumor tissues were obtained from patients through a
protocol approved by the Clinical Research Ethics Board
of the University of British Columbia (UBC) and the
BC Cancer Agency (BCCA). All patients signed a
consent form approved by the Ethics Board (UBC
Ethics Board #: H09-01628 and H04-60131; VCHRI #:
V09-0320 and V07-0058). Animal care and experi-
mental procedures were carried out in accordance
with the guidelines of the Canadian Council of Ani-
mal Care (CCAC) under the approval of the Animal
Care Committee of University of British Columbia
(permit #: A10-0100). The microarray gene expression
data for these tumor lines have been previously
deposited in the NCBI Gene Expression Omnibus
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(GEO) and are freely available under the accession
number GSE41193.
Bioinformatic database analysis
The Oncomine database was used to compare the
expression of CBX2 between metastatic and non-
metastatic PCa [30]. Data was acquired in an unbiased
fashion by compiling all the Oncomine studies with
significantly altered CBX2 expression (p ≤ 0.05). The
cBIO portal (http://www.cbioportal.org/) was used to
assess the genomic alterations affecting the CBX2
locus in PCa. In addition, the MSKCC dataset [31] was
extracted from cBIO portal. Using this dataset, correl-
ation between CBX2 and all other genes were calculated
using the Pearson and Spearman correlation tests.
Cell culture
All cell lines were maintained in RPMI 1640 growth
medium (GIBCO) supplemented with 10 % fetal bovine
serum (GIBCO) at 37 °C and 5 % CO2. For the androgen
depletion experiment, LNCaP cells were initially plated
in conditions described above for 24 h, following which
media was changed to RPMI 1640 (GIBCO) supple-
mented with charcoal-stripped FBS (GIBCO), which has
the property of being completely free of steroid
hormones [40]. This charcoal-stripped media was then
itself supplemented with DHT (10 nM) or not, and the
cells were harvested at 6, 24, and 48 h after media
change for qPCR analysis.
qRT-PCR
RNA was extracted using the RNeasy Kit (Qiagen)
according to the manufacturer’s protocol. NanoDrop
technology (ND-1000, NanoDrop) was used to quantify
extracted RNA, which was subsequently subjected to
reverse transcription using the QuantiTect Kit (Qiagen).
Quantification of cDNA was done using primers from
IDT (see Table 6 for sequences) and SYBR Green
Universal Master Mix (KAPA Biosystems) on an ABIPr-
ism 7900HT platform (Applied Biosystems) as per the
manufacturers’ instructions.
Western blot
Cell lysis was done using radioimmunoprecipitation
assay (RIPA) buffer supplemented with a protease inhibi-
tor cocktail (Roche). Bicinchoninic acid (BCA) protein
assay (Thermo Fisher Scientific) was conducted to
quantify protein concentrations in the resulting
lysates. Fifteen micrograms of proteins were run on a
10 % sodium dodecyl sulfate polyacrylamide gel, trans-
ferred to a nitrocellulose membrane (Bio-Rad), and
subjected to Western blot analysis. Primary rabbit
antibodies specific to CBX2 (Thermo Fisher Scientific,
Cat # PA5-30996, 1:1000) and actin (Thermo Fisher
Scientific, Cat # PA1-16889, 1:4000) were incubated
overnight at 4 °C, and goat anti-rabbit secondary
antibody (Thermo Fisher Scientific, Cat # 31460, 1:15
000) was detected using electrochemiluminescence
(ECL) kit (Thermo Fisher Scientific) according to the
manufacturer’s protocol.
Microscopy
Light microscopy images were obtained using the
Axiovert 40 CFL (Zeiss) and the Axioplan 2 (Zeiss).
siRNA knockdown
Twenty-four hours after seeding, cells at a confluency of
30–50 % were treated with 8 nm CBX2-specific or non-
targeting siRNA (ON-TARGET plus siRNA, Dharma-
con). Lipofectamine 2000 (Invitrogen) was used as the
transfecting agent according to the manufacturer’s
protocol, and cells were subjected to functional assays
24 to 120 h post-transfection.
Caspase 3–7 activity
Seventy-two hours after CBX2 or non-targeting siRNA
treatment in LNCaP and C4-2 (as described earlier),
Table 6 qRT-PCR primers
Gene Direction Sequence (5′-3′)
CBX2 Forward ATCGAGCACGTATTTGTCAC
CBX2 Reverse AGTAATGCCTCAGGTTGAAG
CENPF Forward GAGGACCAACACCTGCTACC
CENPF Reverse GGCTAGTCTTTCCTGTCGGG
CEP55 Forward CCGTTGTCTCTTCGATCGCT
CEP55 Reverse GGCTTCGATCCCCACTTACT
DICER1 Forward TGAAATGCTTGGCGACTCCT
DICER1 Reverse GCCAATTCACAGGGGGATCA
FOXM1 Forward ATAGCAAGCGAGTCCGCATT
FOXM1 Reverse AGCAGCACTGATAAACAAAGAAAGA
HPRT1 Forward GGTCAGGCAGTATAATCCAAAG
HPRT1 Reverse CGATGTCAATAGGACTCCAGATG
INPP5A Forward TGTGACCGCATCCTCATGTC
INPP5A Reverse TGATTCGGAAGGCCAGGAAC
ITGB8 Forward TTTGTCTGCCTGCAAAACGA
ITGB8 Reverse GCACAGGATGCTGCATTTGA
MKI67 Forward TGAGCCTGTACGGCTAAAACA
MKI67 Reverse GGCCTTGGAATCTTGAGCTTT
PIK3R1 Forward GATTCTCAGCAGCCAGCTCTGAT
PIK3R1 Reverse GCAGGCTGTCGTTCATTCCAT
TERT Forward GAGAACAAGCTGTTTGCGGG
TERT Reverse AAGTTCACCACGCAGCCATA
TIMP2 Forward GCGGTCAGTGAGAAGGAAGT
TIMP2 Reverse GGAGGGGGCCGTGTAGATAA
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the relative caspase 3/7 activity was assessed using the
Caspase-Glo 3/7 assay (Promega) according to the
manufacturer’s protocol and chemiluminescence was
measured with a spectrophotometer (Thermo Fisher
Scientific).
MTT analysis
At 1, 3, and 5 days post-treatment with siRNA, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) solution (5 mg/ml, Sigma) was added to media
and incubated for 3.5 h, after which, the cells were
solubilized with dimethyl sulfoxide (DMSO) and
absorbance was read at 570 nm using a spectropho-
tometer (Thermo Fisher Scientific).
Microarray analysis
RNA was extracted from C4-2 cells treated with CBX2-
specific or non-targeting siRNA 55 h post-treatment in
triplicate, using the RNA isolation protocol described
above in the qRT-PCR section. RNA quality was
assessed using the Agilent 2100 Bioanalyzer. Samples
were subjected to microarray analysis using the Agilent
human GE 8x60 v1 array at the Laboratory for
Advanced Genomic Analysis (LAGA) in Vancouver,
BC. Differential gene expression was quantified using
T test unpaired unequal variance (Welch), and p
values were corrected for multiple testing using the
Benjamini-Hochberg correction (p ≤ 0.05).
Immunohistochemistry
The preparation of paraffin-embedded tissue sections and
IHC were carried out as previously described [29, 41]. A
CBX2-specific primary antibody was used (rabbit
polyclonal, Pierce) and was recognized by a goat anti-
rabbit secondary antibody (Vector Laboratory).
Statistical analysis
Unsupervised hierarchical clustering and multivariate
analysis of variance (MANOVA) were conducted
using the R statistical package. Computational ana-
lyses of CBX2-regulated transcripts were carried out
with the IPA software (Qiagen, June 2014 release).
Unless otherwise mentioned, all analyses were done
using p ≤ 0.05 (denoted as * in figures) as the signifi-
cance threshold with the GraphPad Prism software
(version 6).
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